{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:07:24Z","timestamp":1794276444168,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04557-2","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T18:28:35Z","timestamp":1754504915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase II trial of intravenous human dental pulp stem cell therapy for Huntington\u2019s disease: a randomized, double-blind, placebo-controlled study"],"prefix":"10.1186","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03252535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Joyce Macedo Sanches","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-0829","authenticated-orcid":false,"given":"Eduardo","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Valverde","family":"Wenceslau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Hideki","family":"Ynoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kerkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"4557_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, et al. The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391. https:\/\/doi.org\/10.1002\/mds.25075.","journal-title":"Mov Disord"},{"key":"4557_CR2","unstructured":"Sociedade de Neurologia \u2013 Frequ\u00eancia da doen\u00e7a de Huntington no Brasil, <https:\/\/amb.org.br\/sociedades\/sociedade-de-neurologia-frequencia-da-doenca-de-huntington-no-brasil\/> (2023)."},{"key":"4557_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO. Huntington\u2019s disease. Lancet. 2007;369:218\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(07)60111-1.","journal-title":"Lancet"},{"key":"4557_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","volume":"36","author":"S Frank","year":"2022","unstructured":"Frank S, et al. The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study. CNS Drugs. 2022;36:1207\u201316. https:\/\/doi.org\/10.1007\/s40263-022-00956-8.","journal-title":"CNS Drugs"},{"key":"4557_CR5","unstructured":"Huntington\u2019s Disease, <https:\/\/www.ninds.nih.gov\/health-information\/disorders\/huntingtons-disease#toc-how-is-huntington-s-disease-diagnosed-and-treated-> ("},{"key":"4557_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316:40\u201350. https:\/\/doi.org\/10.1001\/jama.2016.8655.","journal-title":"JAMA"},{"key":"4557_CR7","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, et al. Targeting Huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med. 2019;380:2307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1900907.","journal-title":"N Engl J Med"},{"key":"4557_CR8","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMc2300400","volume":"389","author":"P McColgan","year":"2023","unstructured":"McColgan P, et al. Tominersen in adults with manifest Huntington\u2019s disease. N Engl J Med. 2023;389:2203\u20135. https:\/\/doi.org\/10.1056\/NEJMc2300400.","journal-title":"N Engl J Med"},{"key":"4557_CR9","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","volume":"28","author":"A Feigin","year":"2022","unstructured":"Feigin A, et al. Pepinemab antibody blockade of SEMA4D in early Huntington\u2019s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022;28:2183\u201393. https:\/\/doi.org\/10.1038\/s41591-022-01919-8.","journal-title":"Nat Med"},{"key":"4557_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"Huntington Study Group HART Investigators","year":"2013","unstructured":"Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord. 2013;28:1407\u201315. https:\/\/doi.org\/10.1002\/mds.25362.","journal-title":"Mov Disord"},{"key":"4557_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3233\/jhd-190393","volume":"9","author":"A McGarry","year":"2020","unstructured":"McGarry A, et al. Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease. J Huntingtons Dis. 2020;9:173\u201384. https:\/\/doi.org\/10.3233\/jhd-190393.","journal-title":"J Huntingtons Dis"},{"key":"4557_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/jhd-170241","volume":"6","author":"A McGarry","year":"2017","unstructured":"McGarry A, et al. Safety and exploratory efficacy at 36 months in Open-HART, an open-label extension study of pridopidine in Huntington\u2019s disease. J Huntingtons Dis. 2017;6:189\u201399. https:\/\/doi.org\/10.3233\/jhd-170241.","journal-title":"J Huntingtons Dis"},{"key":"4557_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3233\/jhd-200440","volume":"9","author":"A McGarry","year":"2020","unstructured":"McGarry A, et al. Effects of pridopidine on functional capacity in early-stage participants from the PRIDE-HD study. J Huntingtons Dis. 2020;9:371\u201380. https:\/\/doi.org\/10.3233\/jhd-200440.","journal-title":"J Huntingtons Dis"},{"key":"4557_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s1474-4422(18)30391-0","volume":"18","author":"R Reilmann","year":"2019","unstructured":"Reilmann R, et al. Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18:165\u201376. https:\/\/doi.org\/10.1016\/s1474-4422(18)30391-0.","journal-title":"Lancet Neurol"},{"key":"4557_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s1474-4422(23)00454-4","volume":"23","author":"R Reilmann","year":"2024","unstructured":"Reilmann R, et al. Safety and efficacy of laquinimod for Huntington\u2019s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Neurol. 2024;23:243\u201355. https:\/\/doi.org\/10.1016\/s1474-4422(23)00454-4.","journal-title":"Lancet Neurol"},{"key":"4557_CR16","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/bcp.15635","volume":"89","author":"J Gamez","year":"2023","unstructured":"Gamez J, et al. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington\u2019s disease. Br J Clin Pharmacol. 2023;89:1656\u201364. https:\/\/doi.org\/10.1111\/bcp.15635.","journal-title":"Br J Clin Pharmacol"},{"key":"4557_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1212\/wnl.0000000000004209","volume":"89","author":"SM Hersch","year":"2017","unstructured":"Hersch SM, et al. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology. 2017;89:594\u2013601. https:\/\/doi.org\/10.1212\/wnl.0000000000004209.","journal-title":"Neurology"},{"key":"4557_CR18","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/mds.27010","volume":"32","author":"C Verny","year":"2017","unstructured":"Verny C, et al. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington\u2019s disease. Mov Disord. 2017;32:932\u20136. https:\/\/doi.org\/10.1002\/mds.27010.","journal-title":"Mov Disord"},{"key":"4557_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1212\/wnl.0000000000000187","volume":"82","author":"HD Rosas","year":"2014","unstructured":"Rosas HD, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 2014;82:850\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000000187.","journal-title":"Neurology"},{"key":"4557_CR20","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/mds.26308","volume":"30","author":"JJ Ferreira","year":"2015","unstructured":"Ferreira JJ, et al. Ethyl-eicosapentaenoic acid treatment in Huntington\u2019s disease: a placebo-controlled clinical trial. Mov Disord. 2015;30:1426\u20139. https:\/\/doi.org\/10.1002\/mds.26308.","journal-title":"Mov Disord"},{"key":"4557_CR21","doi-asserted-by":"publisher","first-page":"13625","DOI":"10.1073\/pnas.240309797","volume":"97","author":"S Gronthos","year":"2000","unstructured":"Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 2000;97:13625\u201330. https:\/\/doi.org\/10.1073\/pnas.240309797.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4557_CR22","doi-asserted-by":"publisher","first-page":"1400533","DOI":"10.3389\/fimmu.2024.1400533","volume":"15","author":"I Kerkis","year":"2024","unstructured":"Kerkis I, da Silva AP, Araldi RP. The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions. Front Immunol. 2024;15:1400533. https:\/\/doi.org\/10.3389\/fimmu.2024.1400533.","journal-title":"Front Immunol"},{"key":"4557_CR23","unstructured":"Kerkis I, Valverde Wenceslau C, Pinheiro Araldi R. Recent Update on Mesenchymal Stem Cells. Ahmed Al-Anazi K (eds) 2024; IntechOpen."},{"key":"4557_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.17311\/pharmacologia.2023.72.95","volume":"14","author":"RP Araldi","year":"2023","unstructured":"Araldi RP, et al. Unique transcriptional signatures observed in stem cells from the dental pulp of deciduous teeth produced on a large scale. Pharmacologia. 2023;14:72\u201395. https:\/\/doi.org\/10.17311\/pharmacologia.2023.72.95.","journal-title":"Pharmacologia"},{"key":"4557_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126827","author":"KF Azman","year":"2022","unstructured":"Azman KF, Zakaria R. Recent advances on the role of brain-derived neurotrophic factor (BDNF) in neurodegenerative diseases. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23126827.","journal-title":"Int J Mol Sci"},{"key":"4557_CR26","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","volume":"11","author":"S Bathina","year":"2015","unstructured":"Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11:1164\u201378. https:\/\/doi.org\/10.5114\/aoms.2015.56342.","journal-title":"Arch Med Sci"},{"key":"4557_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fncel.2014.00254","volume":"8","author":"M Baydyuk","year":"2014","unstructured":"Baydyuk M, Xu B. BDNF signaling and survival of striatal neurons. Front Cell Neurosci. 2014;8:254. https:\/\/doi.org\/10.3389\/fncel.2014.00254.","journal-title":"Front Cell Neurosci"},{"key":"4557_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cells11101664","author":"CV Wenceslau","year":"2022","unstructured":"Wenceslau CV, et al. Restoration of BDNF, DARPP32, and D2R expression following intravenous infusion of human immature dental pulp stem cells in Huntington\u2019s disease 3-NP rat model. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11101664.","journal-title":"Cells"},{"key":"4557_CR29","unstructured":"Gamarra L, Cintra L, G\u00e1rate AP. Relat\u00f3rio final do estudo de biodistribui\u00e7\u00e3o do produto NestaCell\u00ae. 72 Centro de Experimenta\u00e7\u00e3o e Treinamento em Cirurgia (CETEC) do Instituto Israelita de Ensino e Pesquisa Hospital Albert Einstein. 2022."},{"key":"4557_CR30","unstructured":"ESTUDO DE TOXICIDADE DA TERAPIA CELULAR NO TRATAMENTO DE NEURODEGENERA\u00c7\u00c3O CEREBRAL. Report No. Final, 69 (Instituto Israelita de Ensino e Pesquisa Hospital Albert Einstein, 2022)."},{"key":"4557_CR31","unstructured":"Fernandes JMS et al. Phase I, Two dose levels, open-label trial of intravenous human dental pulp stem cell therapy in Huntington\u2019s disease. Under Review by Stem Cell Research & Therapy."},{"key":"4557_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000099617","volume":"184","author":"I Kerkis","year":"2006","unstructured":"Kerkis I, et al. Isolation and characterization of a population of immature dental pulp stem cells expressing OCT-4 and other embryonic stem cell markers. Cells Tissues Organs. 2006;184:105\u201316. https:\/\/doi.org\/10.1159\/000099617.","journal-title":"Cells Tissues Organs"},{"key":"4557_CR33","doi-asserted-by":"publisher","first-page":"e39885","DOI":"10.1371\/journal.pone.0039885","volume":"7","author":"NF Lizier","year":"2012","unstructured":"Lizier NF, et al. Scaling-up of dental pulp stem cells isolated from multiple niches. PLoS ONE. 2012;7:e39885. https:\/\/doi.org\/10.1371\/journal.pone.0039885.","journal-title":"PLoS ONE"},{"key":"4557_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315\u20137. https:\/\/doi.org\/10.1080\/14653240600855905.","journal-title":"Cytotherapy"},{"key":"4557_CR35","unstructured":"Kerkis I, Kerkis A. Compositions comprising stem cells expressing mesenchymal and neuronal markers and uses thereof to treat neurological disease. US20160184366A1."},{"key":"4557_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","volume":"76","author":"JM \u00c1lvaro-Gracia","year":"2017","unstructured":"\u00c1lvaro-Gracia JM, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial. Ann Rheum Dis. 2017;76:196\u2013202. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208918.","journal-title":"Ann Rheum Dis"},{"key":"4557_CR37","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/sctm.16-0372","volume":"6","author":"DC Chambers","year":"2017","unstructured":"Chambers DC, et al. Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First-in-Man Study. Stem Cells Transl Med. 2017;6:1152\u20137. https:\/\/doi.org\/10.1002\/sctm.16-0372.","journal-title":"Stem Cells Transl Med"},{"key":"4557_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jcyt.2014.10.009","volume":"17","author":"A Chullikana","year":"2015","unstructured":"Chullikana A, et al. Randomized, double-blind, phase I\/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy. 2015;17:250\u201361. https:\/\/doi.org\/10.1016\/j.jcyt.2014.10.009.","journal-title":"Cytotherapy"},{"key":"4557_CR39","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","volume":"54","author":"JM Hare","year":"2009","unstructured":"Hare JM, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2009.06.055.","journal-title":"J Am Coll Cardiol"},{"key":"4557_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","volume":"12","author":"DK Packham","year":"2016","unstructured":"Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine. 2016;12:263\u20139. https:\/\/doi.org\/10.1016\/j.ebiom.2016.09.011.","journal-title":"EBioMedicine"},{"key":"4557_CR41","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.2337\/dc14-2830","volume":"38","author":"JS Skyler","year":"2015","unstructured":"Skyler JS, Fonseca VA, Segal KR, Rosenstock J. Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care. 2015;38:1742\u20139. https:\/\/doi.org\/10.2337\/dc14-2830.","journal-title":"Diabetes Care"},{"key":"4557_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/s2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2015","unstructured":"Wilson JG, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3:24\u201332. https:\/\/doi.org\/10.1016\/s2213-2600(14)70291-7.","journal-title":"Lancet Respir Med"},{"key":"4557_CR43","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/circresaha.117.310712","volume":"121","author":"J Bartolucci","year":"2017","unstructured":"Bartolucci J, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res. 2017;121:1192\u2013204. https:\/\/doi.org\/10.1161\/circresaha.117.310712.","journal-title":"Circ Res"},{"key":"4557_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5966\/sctm.2012-0034","volume":"1","author":"M Shi","year":"2012","unstructured":"Shi M, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1:725\u201331. https:\/\/doi.org\/10.5966\/sctm.2012-0034.","journal-title":"Stem Cells Transl Med"},{"key":"4557_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3727\/096368916x694373","volume":"26","author":"YA Tsai","year":"2017","unstructured":"Tsai YA, et al. Treatment of spinocerebellar ataxia with mesenchymal stem cells: a phase I\/IIa clinical study. Cell Transplant. 2017;26:503\u201312. https:\/\/doi.org\/10.3727\/096368916x694373.","journal-title":"Cell Transplant"},{"key":"4557_CR46","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar4520","volume":"16","author":"D Wang","year":"2014","unstructured":"Wang D, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16:R79. https:\/\/doi.org\/10.1186\/ar4520.","journal-title":"Arthritis Res Ther"},{"key":"4557_CR47","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3727\/096368911X582769c","volume":"22","author":"D Wang","year":"2013","unstructured":"Wang D, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013;22:2267\u201377. https:\/\/doi.org\/10.3727\/096368911X582769c.","journal-title":"Cell Transplant"},{"key":"4557_CR48","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jcyt.2016.11.005","volume":"19","author":"YC Zhang","year":"2017","unstructured":"Zhang YC, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation. Cytotherapy. 2017;19:194\u20139. https:\/\/doi.org\/10.1016\/j.jcyt.2016.11.005.","journal-title":"Cytotherapy"},{"key":"4557_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"HS Group","year":"1996","unstructured":"Group HS. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord. 1996;11:136\u201342. https:\/\/doi.org\/10.1002\/mds.870110204.","journal-title":"Mov Disord"},{"key":"4557_CR50","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/mds.28201","volume":"35","author":"AC Bachoud-L\u00e9vi","year":"2020","unstructured":"Bachoud-L\u00e9vi AC. Human fetal cell therapy in huntington\u2019s disease: a randomized, multicenter. Phase II Trial Mov Disord. 2020;35:1323\u201335. https:\/\/doi.org\/10.1002\/mds.28201.","journal-title":"Phase II Trial Mov Disord"},{"key":"4557_CR51","doi-asserted-by":"publisher","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","volume":"12","author":"H Gelderblom","year":"2017","unstructured":"Gelderblom H, et al. Bupropion for the treatment of apathy in Huntington\u2019s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE. 2017;12:e0173872. https:\/\/doi.org\/10.1371\/journal.pone.0173872.","journal-title":"PLoS ONE"},{"key":"4557_CR52","unstructured":"Wechsler D. WAIS III \u2013 Escala De Intelig\u00eancia Wechsler Para Adultos \u2013 Manual Para Administra\u00e7\u00e3o E Avalia\u00e7\u00e3o. 1 edn, 2004."},{"key":"4557_CR53","volume-title":"A compendium of neuropsychological tests: administration, norms, and commentary","author":"O Spreen","year":"1998","unstructured":"Spreen O, Spreen BPPO, Strauss E, Strauss PPE. A compendium of neuropsychological tests: administration, norms, and commentary. USA: Oxford University Press; 1998."},{"key":"4557_CR54","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaneurol.2013.4408","volume":"70","author":"ER Dorsey","year":"2013","unstructured":"Dorsey ER, et al. Natural history of Huntington disease. JAMA Neurol. 2013;70:1520\u201330. https:\/\/doi.org\/10.1001\/jamaneurol.2013.4408.","journal-title":"JAMA Neurol"},{"key":"4557_CR55","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2003000500035","author":"PHF Bertolucci","year":"2003","unstructured":"Bertolucci PHF, Nitrini R. Proposta de uma vers\u00e3o brasileira para a escala ADCS-CGIC. Arq Neuropsiquiatr. 2003. https:\/\/doi.org\/10.1590\/S0004-282X2003000500035.","journal-title":"Arq Neuropsiquiatr"},{"key":"4557_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362. https:\/\/doi.org\/10.1136\/jnnp.23.1.56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4557_CR57","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/1742395312467658","volume":"9","author":"M Worboys","year":"2013","unstructured":"Worboys M. The hamilton rating scale for depression: the making of a \u201cgold standard\u201d and the unmaking of a chronic illness, 1960\u20131980. Chronic Illn. 2013;9:202\u201319. https:\/\/doi.org\/10.1177\/1742395312467658.","journal-title":"Chronic Illn"},{"key":"4557_CR58","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0021-9681(72)90027-6","volume":"25","author":"A Keys","year":"1972","unstructured":"Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972;25:329\u201343. https:\/\/doi.org\/10.1016\/0021-9681(72)90027-6.","journal-title":"J Chronic Dis"},{"key":"4557_CR59","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/ije\/dyu058","volume":"43","author":"A Keys","year":"2014","unstructured":"Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. Int J Epidemiol. 2014;43:655\u201365. https:\/\/doi.org\/10.1093\/ije\/dyu058.","journal-title":"Int J Epidemiol"},{"key":"4557_CR60","unstructured":"MRICloud. <https:\/\/mricloud.org\/> 2022."},{"key":"4557_CR61","unstructured":"FDA. Ed Food and drug administration 2015; 27."},{"key":"4557_CR62","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJ, van Roon-Mom WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015;87:90\u2013103. https:\/\/doi.org\/10.1016\/j.addr.2015.03.008.","journal-title":"Adv Drug Deliv Rev"},{"key":"4557_CR63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1590\/s1980-5764-2016dn1004006","volume":"10","author":"MS Haddad","year":"2016","unstructured":"Haddad MS, Wenceslau CV, Pompeia C, Kerkis I. Cell-based technologies for Huntington\u2019s disease. Dement Neuropsychol. 2016;10:287\u201395. https:\/\/doi.org\/10.1590\/s1980-5764-2016dn1004006.","journal-title":"Dement Neuropsychol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04557-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T18:28:38Z","timestamp":1754504918000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04557-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4557"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04557-2","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol \u201c\n                      Avalia\u00e7\u00e3o da Dose-Resposta do Produto Investigacional Cellavita HD ap\u00f3s Aplica\u00e7\u00e3o Intravenosa em Participantes com Doen\u00e7a de Huntington\n                      \u201d was first approved by the ethical committee of\n                      Faculdade de Medicina de Jundiai\n                      (Approval number: 52375916.1.0000.5412) on 4, February 2016, conformed to the ICH-E6 guidelines. The last amendment was approved on December 26, 2019. All participants provided written informed consent before recruitment. This study was registered on clinicaltrials.gov (Identifier: NCT03252535). The investigational product evaluated in this study was originally developed under the name Cellavita HD. In March 2020, it was registered under the trademark NestaCell\u00ae. Both names refer to the same cell-based product. In this manuscript, the current designation NestaCell\u00ae is used consistently; however, the original name Cellavita HD is retained when citing regulatory documents\u2014such as the ethics committee approval\u2014where that designation was originally employed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients, all authors, and the Sponsor for the publication of this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EP & CVW are employees of the study sponsor. IK & CVW are listed as inventors on the NestaCell\u00ae patent and hold associated commercial rights. JMSF, LF & LHY declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}